Showing 421 - 440 results of 102,654 for search '(( 50 ((teer decrease) OR (mean decrease)) ) OR ( 5 ((we decrease) OR (a decrease)) ))', query time: 1.63s Refine Results
  1. 421
  2. 422
  3. 423
  4. 424
  5. 425
  6. 426

    Dopaminergic Neurodegeneration in the Mouse Is Associated with Decrease of Viscoelasticity of Substantia Nigra Tissue by Elisabeth G. Hain (542261)

    Published 2016
    “…After treatment cessation, we observed opposed viscoelastic changes in the midbrain, hippocampus and SN with the midbrain showing a gradual rise and the hippocampus a distinct transient increase of viscous and elastic parameters, while viscosity and–to a lesser extent—elasticity in the SN decreased over time. …”
  7. 427
  8. 428

    Down-regulation of Gli decreased ovarian cancer cell migration and invasion. by Qi Chen (144168)

    Published 2014
    “…<p>(<b>A</b>) Exposure to GANT61 (30 µM; 48 hr) reduces expression of both Gli1 and Gli2 protein, determined by Western blot. …”
  9. 429
  10. 430

    Loss of C9orf72 decreases mTOR activation. by Janet Ugolino (3359054)

    Published 2016
    “…C9orf72-/- MEF cells show a decrease in p-S6K1 when compared with wild-type cells. …”
  11. 431
  12. 432
  13. 433

    Beneficial effects of a gait used while wearing a kimono to decrease the knee adduction moment in healthy adults by Susumu Ota (4167205)

    Published 2017
    “…Most of the modifications, however, involve voluntary changes in leg alignment. Here we investigated the biomechanical effects for reducing the KAM of a walking style with a small trunk rotation and arm swing gait, which is a natural walking style used while wearing a kimono (Nanba walk) that shifts the ground reaction force toward the stance leg (reduced lever arm). …”
  14. 434

    IgG-mediated systemic anaphylaxis decreased in BasoDTR mice. by Kunie Matsuoka (400418)

    Published 2013
    “…<p>(A) BasoDTR mice (n = 4 per group) were treated once i.p. with 25 or 50 µg/kg of DT or PBS at 4 days prior to and were i.v. injected with 500 µg rat anti-FcγRII/III (2.4G2) antibodies in 200 µl PBS. …”
  15. 435
  16. 436
  17. 437
  18. 438
  19. 439
  20. 440